Defining the Prognostic Significance of BRAF V600E in Early-Stage Colon Cancer: A Systematic Review and Meta-Analysis

Background: BRAF mutations are found in 10% of colon cancers (CCs) and are associated with poor prognosis in metastatic disease. BRAF V600E predicts sensitivity to cetuximab + encorafenib in the metastatic setting. With new trials testing encorafenib-containing regimens for early-stage CC, we sought...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Matthew Dankner, Laurie-Rose Dubé, Mark Sorin, Andrew J. B. Stein, Alexander Nowakowski, Changsu Lawrence Park, Jamie Magrill, Anna-Maria Lazaratos, Joan Miguel Romero, Gerald Batist, Petr Kavan, April A. N. Rose, Kim Ma
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	MDPI AG 2025-11-01
Edice:	Current Oncology
Témata:	BRAF encorafenib colon cancer adjuvant targeted therapy
On-line přístup:	https://www.mdpi.com/1718-7729/32/11/624
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!